Company intelligence / Profile preview

Centera Bioscience

Tempe, Arizona, United Statescenterabioscience.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Centera Bioscience operated primarily as a retailer and distributor of nootropic compounds—substances marketed for cognitive enhancement. The company pleaded guilty in 2023 to distributing misbranded prescription drugs not approved by the FDA. Products included tianeptine, phenibut, adrafinil, and various racetams. These were sold directly to consumers without prescriptions under the brand "Nootropics Depot." There is no evidence that any products underwent clinical trials or received regulatory approval.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Centera Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centera Bioscience.

Explore the full profile